Intended for healthcare professionals

News

Covid-19: RECOVERY trial will evaluate “antiviral antibody cocktail”

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3584 (Published 15 September 2020) Cite this as: BMJ 2020;370:m3584

Read our latest coverage of the coronavirus outbreak

  1. Elisabeth Mahase
  1. The BMJ

The RECOVERY trial, which discovered that dexamethasone shows benefit in patients seriously ill with covid-19, will investigate the impact of an “antiviral antibody cocktail” specifically designed for covid-19, known as REGN-COV2.

The phase III trial at the University of Oxford has been evaluating different treatment candidates for the virus from early on in the pandemic. Its researchers have now announced that it will assess the effects of adding REGN-COV2 to the usual standard of care, versus standard care alone, on all cause mortality 28 days after randomisation.

The investigation, …

View Full Text